
Opinion|Videos|May 21, 2024
Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 Vaccination in Medically Complex Adults
2
FDA Grants Accelerated Approval to Iberdomide Combination for Multiple Myeloma
3
Generic Semaglutide May Make GLP-1 Therapy Cost-Effective in T2D
4
Active Surveillance Becomes Dominant Strategy for Low-Risk Prostate Cancer, Reaching 93% Among Veterans
5



































































































